GI Innovation (KOSDAQ:A358570) - Stock Price, News & Analysis

A358570 Stock Overview

A bio-venture company, engages in the research and development of protein new drugs. More details

A358570 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Volatile share price over the past 3 months compared to the KR market

GI Innovation, Inc. Competitors

BioNote

KOSE:A377740

₩479.7b

Prestige Biologics

KOSDAQ:A334970

₩435.1b

Bioneer

KOSDAQ:A064550

₩522.7b

EuBiologics

KOSDAQ:A206650

₩480.4b

Price History & Performance

Summary of all time highs, changes and price drops for GI Innovation
Historical stock prices
Current Share Price	₩10,250.00
52 Week High	₩16,340.00
52 Week Low	₩8,510.00
Beta	0
11 Month Change	-30.93%
3 Month Change	2.30%
1 Year Change	8.70%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.23%

Recent updates

Shareholder Returns

	A358570	KR Biotechs	KR Market
7D	-10.3%	-4.0%	-0.7%
1Y	8.7%	23.9%	-4.1%

Return vs Industry: A358570 underperformed the KR Biotechs industry which returned 23.9% over the past year.

Return vs Market: A358570 exceeded the KR Market which returned -4.1% over the past year.

Price Volatility

Is A358570's price volatile compared to industry and market?
A358570 volatility
A358570 Average Weekly Movement	9.4%
Biotechs Industry Average Movement	8.0%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A358570's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A358570's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2017	n/a	n/a	www.gi-innovation.com

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases.

GI Innovation, Inc. Fundamentals Summary

How do GI Innovation's earnings and revenue compare to its market cap?
A358570 fundamental statistics
Market cap	₩453.68b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A358570 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A358570 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A358570 perform over the long term?

See historical performance and comparison

GI Innovation KOSDAQ:A358570 Stock Report